Emergent BioSolutions has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain for medical countermeasures that address chemical warfare agents. The contract is comprised of a five-year base period of performance along with five one-year option periods with a total contract value of a minimum of approximately $7 million to a maximum of $100 million over the contract’s period of performance. Emergent will be supplying two of its current medical countermeasures addressing chemical threats: the Trobigard atropine sulfate/obidoxime chloride auto-injector, a drug-device combination product for emergency use in the event of nerve agent or organophosphate poisoning; and RSDL (Reactive Skin Decontamination Lotion Kit), which is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin.
 
“Emergent is pleased with this follow-on opportunity to meet the U.S. government’s need for medical countermeasures that enhance the security of U.S. diplomats and other Chief of Mission personnel engaged in high-risk environments worldwide,” said Doug White, senior vice president and head of the devices business unit, Emergent BioSolutions. “Our mission, to protect and enhance life, has been at the core of our 20-year history of partnering with governments. We look forward to successfully completing deliveries of our Trobigard auto-injector under our 2017 contract and to our continued partnership with the State Department as we expand our portfolio of solutions to address existing and emerging chemical warfare agents for the long-term.”
 
“One of our most important responsibilities is to respond to critical threats to Department diplomatic missions overseas and to maintain the safety of deployed employees,” said William Walters, managing director of operational medicine, U.S. Department of State. “This begins with establishing a stable supply chain of medical countermeasures and ensuring adequate stockpiles as we equip ourselves with the tools that best enable a safe, accurate, and timely response to the highest risk chemical agents.”
 
Under this IDIQ contract, Emergent will maintain the capability to manufacture and deliver various medical countermeasures defined by the Department of State, including the Trobigard auto-injector, Reactive Skin Decontamination Lotion Kit, and auto-injector training devices.